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Abstract
Aims: Compared with bare metal stents (BMS), early generation drug-eluting stents (DES) reduce the risk of 
revascularisation in patients with ST-elevation myocardial infarction (STEMI) at the expense of an increased 
risk of very late stent thrombosis (ST). Durable polymer coatings for controlled drug release have been iden-
tified as a potential trigger for these late adverse events and this has led to the development of newer genera-
tion DES with durable and biodegradable polymer surface coatings with improved biocompatibility. In 
a recent all-comers trial, biolimus-eluting stents with a biodegradable polymer surface coating were found to 
reduce the risk of very late ST by 80% compared with sirolimus-eluting stents with durable polymer, which 
also translated into a lower risk of cardiac death and myocardial infarction (MI) beyond one year.
Methods and results: The multicentre COMFORTABLE AMI trial (NCT00962416) randomly assigned 1,161 
patients to treatment with biolimus-eluting stents with biodegrable polymer and bare metal stents of otherwise 
identical design at 11 international sites. The primary endpoint is a composite of cardiac death, target-vessel MI 
and target lesion revascularisation at one year. Assuming a relative risk reduction of 40% in event rates of the 
primary endpoint in favour of biolimus-eluting stents with biodegradable polymer, 1,064 patients will provide 
80% power to demonstrate superiority. Clinical follow-up will be continued through five years.
Conclusions: The COMFORTABLE AMI trial will determine whether biolimus-eluting stents with biode-
gradable polymer are superior to bare metal stents of otherwise identical design. This is the first randomised 
controlled trial (RCT) investigating DES with a biodegradable polymer surface coating for drug release in the 
treatment of patients with STEMI.
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Rationale
Early generation drug-eluting stents (DES), namely sirolimus-elut-
ing stents (SES) and paclitaxel-eluting stents (PES) have been com-
pared with bare metal stents (BMS) in the setting of ST-elevation 
MI (STEMI) in several randomised controlled trials enrolling more 
than 7,000 patients to date. A reduction in major adverse cardiovas-
cular events (MACE) was consistently observed and mainly related 
to a lower risk of repeat revascularisation procedures1-7. Brar and 
colleagues compared outcomes between early generation DES and 
BMS8 in a meta-analysis of 7,352 STEMI patients and reported 
a 56% lower risk of repeat revascularisation in favour of DES with-
out differences in the risk of death, MI and ST. Notwithstanding, 
there remains a nagging concern regarding the safety of DES in 
STEMI patients particularly during long-term follow-up. Histo-
pathologic analysis of autopsy specimens revealed more inflamma-
tion, fibrin deposition and uncovered struts among lesions treated 
with early generation DES in patients with acute MI compared to 
those with stable lesions, suggesting a differential healing response 
depending on underlying plaque morphology9,10. Similar observa-
tions were obtained in intravascular imaging studies10,11. Late 
acquired stent malapposition – a potential trigger of very late stent 
thrombosis12,13 – was more common among DES than BMS in 
STEMI patients in the IVUS substudy of the MISSION study and 
HORIZON-AMI14,15 trial. The notion of a differential healing 
response between DES and BMS in STEMI patients was further 
substantiated by the OCT substudy of the HORIZON-AMI trial, 
which observed a higher rate of uncovered and malapposed struts 
among DES treated lesions at 13 months – a pattern much like the 
one observed in autopsy reports16.
A recent meta-analysis17 including 7,867 STEMI patients com-
pared clinical outcomes between early generation DES and BMS 
during long-term follow-up and observed an important treatment 
effect over time. Overall outcomes showed improved efficacy with 
DES whereas safety parameters were similar. Of note, during long-
term follow-up beyond one year, the risk of definite or probable stent 
thrombosis (ST) was significantly higher with early generation DES 
with a trend towards an increased risk of MI. In view of the late harm 
associated with early generation DES implanted among patients with 
STEMI, uncertainty continues to prevail regarding the optimal use of 
DES in this clinical setting18. While previous studies among patients 
with STEMI used early generation DES, newer generation devices 
with drug release from durable or biodegradable polymer surface 
coatings may provide the basis for improved biocompatibility and 
vascular healing19. As for DES using durable polymers, an everoli-
mus-eluting stent (XIENCE®; Abbott Vascular, Redwood City, CA, 
USA) has been tested against a bare metal stent of otherwise identical 
design in the EXAMINATION trial. The primary endpoint of this 
study was the composite of death, MI and revascularisation, which 
was assessed at one year20.
DES with biodegradable polymer coating provide controlled 
drug release with subsequent degradation of the polymer material, 
thereby eliminating the inflammatory stimulus potentially responsi-
ble for late adverse events. Biolimus-eluting stents were designed 
with a biodegradable polymer (polylactic acid) applied to the stent’s 
abluminal surface, which is metabolised to water and carbon diox-
ide within six to nine months21,22. Biolimus is a highly lipophilic 
sirolimus analogue and inhibits proliferation of smoothmuscle cells 
by inducing reversible cell cycle arrest at gap 0 (G0) with similar 
potency to sirolimus.
Biolimus-eluting stents with biodegradable polymer 
(BioMatrix®; Biosensors Inc, Morges, Switzerland) have been 
directly compared with sirolimus-eluting stents with durable pol-
ymer (Cypher® SELECT; Cordis, Miami Lakes, FL, USA) in the 
large scale, randomised LEADERS trial. Non-inferiority of bioli-
mus-eluting stents was established through four years of follow-
up. During the late time period (1-4 years), the use of biodegradable 
polymer based biolimus-eluting stents resulted in a 80% relative 
risk reduction of very late definite ST, which was associated with 
a significant reduction in ischaemic events (cardiac death or MI) 
between one and four years23. Of note, a stratified analysis accord-
ing to pre-specified patient characteristics suggested a pronounced 
reduction in MACE among the subgroup of patients presenting 
with STEMI at baseline (Figure 1). The improved outcome of 
a device with biodegradable as opposed to durable polymer sur-
face coating in lesions with ruptured plaques further supports the 
notion of the improved biocompatibility of biolimus-eluting 
stents during long-term follow-up. As the results of a stratified 
analysis are only hypothesis-generating, we designed a ran-
domised controlled trial comparing biolimus-eluting stents with 
biodegradable polymer with bare metal stents of otherwise identi-
cal design (Gazelle®; Biosensors Inc, Morges, Switzerland) in 
order to validate the safety and efficacy in the high-risk subset of 
patients with STEMI (COMFORTABLE AMI trial).
The synthesis of available data suggests that biolimus-eluting 
stents with biodegradable polymer potentially combine the advan-
tages of drug-eluting stents compared with bare metal stents during 
the first year after implantation – namely the well-known inhibition 
of neointimal hyperplasia and an early antithrombogenic effect as 
proposed in in vitro investigations by Kolandaivelu and colleagues24. 
Upon biodegradation of the polymer during the time period beyond 
one year, biolimus-eluting stents with biodegradable polymer should 
show a performance more like bare metal stents and therefore prevent 
late adverse events previously linked to durable polymers.
In addition to advances in stent design, progress has been 
achieved in terms of interventional procedure and adjuvant anti-
platelet and antithrombotic therapy. Namely, the systematic use of 
thrombus aspiration prior to stent implantation has improved out-
comes following primary PCI25. Moreover, high dose clopidogrel 
pre-treatment led to a 42% relative risk reduction of definite ST in 
the CURRENT-OASIS 726 study. Novel oral P2Y12 inhibitors such 
as prasugrel27 and ticagrelor28 have been shown to reduce the risk of 
cardiac death, MI and stroke, as well as the risk of stent thrombosis 
compared with clopidogrel among patients with STEMI. Therefore, 
it remains to be determined whether newer generation DES in com-
bination with the above-mentioned novel therapeutic strategies 
may further improve outcomes vis-à-vis bare metal stents.
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Design
STUDY	DESIGN	AND	PRIMARY	HYPOTHESIS
The COMFORTABLE AMI trial is a randomised, assessor blind, 
international, multicentre trial comparing biolimus-eluting stents 
with biodegradable polymer with bare metal stents of otherwise 
identical design implanted into culprit lesions of patients with 
STEMI. The trial was designed and the protocol written by the 
steering committee (LR, PJ, SW), and managed by the Clinical 
Trials Unit Bern, Switzerland. The study is powered to examine 
the primary hypothesis that a biolimus-eluting stent with biode-
gradable polymer is superior to a bare metal stent in the setting of 
STEMI in terms of major adverse cardiac events (MACE) – 
a composite endpoint of cardiac death, target vessel MI and target 
lesion revascularisation at one year.
STATISTICAL	ANALYSIS
On the basis of results from the HORIZON and LEADERS trials (sub-
group analysis in STEMI patients), we assumed an incidence of MACE 
(the primary endpoint) of 14% up to one year in the bare metal stent 
group with a relative risk reduction of 0.60 in favour of biolimus-eluting 
stents. Enrolment of 1,064 patients will provide 80% power to detect a 
relative risk of 0.60 at a two-sided alpha of 0.05. All enrolled patients will 
be included in the analysis of primary and secondary clinical outcomes 
according to the intention-to-treat principle. We will use a Cox propor-
tional hazards model to compare clinical outcomes between the groups.
STUDY	POPULATION
Patients aged 18 years or older with ST-elevations in at least two con-
tiguous leads or new left bundle branch block presenting within 
ame BES SES RR (95%CI)
25 -5 1 2 4
p p-interaction
Overall 160 (18.7) 192 (22.6) 0.81 (0.66 to 1.00) 0.050
Diabetes mellitus 0.108
Yes 65 (29.1) 56 (29.3) 1.00 (0.70 to 1.44) 0.980
No 94 (14.8) 136 (20.6) 0.70 (0.54 to 0.91) 0.007
Acute coronary syndrome 0.563
Yes 82 (17.4) 106 (22.4) 0.76 (0.57 to 1.01) 0.061
No 77 (19.9) 86 (22.8) 0.86 (0.63 to 1.17) 0.343
ST-elevation MI 0.043
Yes 15 (11.1) 32 (22.9) 0.45 (0.24 to 0.83) 0.009
No 144 (19.9) 160 (22.5) 0.88 (0.70 to 1.10) 0.262
Left anterior 0.544
Yes 73 (17.9) 85 (20.4) 0.86 (0.63 to 1.18) 0.362
No 86 (19.2) 107 (24.8) 0.76 (0.57 to 1.01) 0.056
Multivessel disease 0.705
Yes 44 (21.1) 48 (27.3) 0.75 (0.49 to 1.13) 0.164
No 115 (17.7) 144 (21.4) 0.82 (0.64 to 1.05) 0.110
Off label use 0.827
Yes 139 (20.0) 165 (24.8) 0.79 (0.63 to 0.99) 0.037
No 20 (12.5) 27 (14.8) 0.84 (0.47 to 1.51) 0.563
De novo lesions 0.965
Yes 138 (17.5) 165 (21.3) 0.81 (0.64 to 1.01) 0.066
No 21 (30.9) 27 (36.5) 0.82 (0.46 to 1.45) 0.494
Small-vessel disease 0.213
Yes 119 (20.3) 131 (23.1) 0.88 (0.68 to 1.12) 0.297
No 40 (14.8) 61 (21.8) 0.65 (0.44 to 0.97) 0.033
Long lesions 0.408
Yes 53 (20.2) 63 (28.0) 0.70 (0.49 to 1.01) 0.057
No 106 (17.8) 129 (20.7) 0.85 (0.65 to 1.10) 0.207
Figure 1. Stratified analysis of the primary endpoint MACE  in the LEADERS trial at four years23. Reprinted from The Lancet, Vol. 378,  with kind 
permission from Elsevier.
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24 hours of onset of pain are eligible if a culprit lesion is identified 
during coronary angiography. Selection criteria are broad, reflecting 
routine clinical practice (Table 1).
All patients will provide a first written consent prior to the randomi-
sation procedure following oral information, whereas a second written 
informed consent will be obtained with the patient in a stable enough 
condition to read and understand the study-specific patient information. 
Between 19 September 2009 and 25 January 2010 (16 months), a total 
Table 1. Inclusion and exclusion criteria.
Inclusion	criteria
1 Age ≥18 years
2 Chest pain >10 min
3 Primary PCI within 24 hours of symptom onset
4 ST-segment elevation of >1 mm in >2 contiguous leads, or 
(presumably new) left bundle branch block, or true posterior MI 
with ST depression of >1 mm in >2 contiguous anterior leads
5 Presence of at least one acute infarct artery target vessel with 
one or more coronary artery stenoses in a native coronary 
artery from 2.25 to 4.0 mm in diameter that can be covered 
with one or multiple stents
Exclusion	criteria
1 Female of childbearing potential (age <50 years and last 
menstruation within the last 12 months), who had not 
undergone tubal ligation, ovariectomy or hysterectomy
2 Known intolerance to aspirin, clopidogrel, heparin, stainless 
steel, biolimus or contrast material
3 Inability to provide informed consent
4 Currently participating in another trial before reaching first 
endpoint
5 Mechanical complications of acute myocardial infarction
6 Acute myocardial infarction secondary to stent thrombosis
7 Planned surgery within 6 months of PCI unless dual antiplatelet 
therapy is maintained throughout the perisurgical period
8 Non-cardiac comorbid conditions with life expectancy <1year 
9 History of bleeding diathesis or known coagulopathy
10 Use of vitamin K antagonists
Table 2. Patient recruitment overview.
Centre Recruitment period
Number of 
recruited patients
Cardiology Department, Bern University Hospital, Bern, Switzerland 17 September 2009 until 25 January 2011 250
Cardiac Catheterisation Laboratory, Rigshospitalet, Copenhagen, Denmark 26 January 2010 until 25 January 2011 173
Clinical Centre of Serbia, Belgrade, Serbia 7 May 2010 until 1 November 2010 172
Bristol Heart Institute, Bristol, United Kingdom 1July 2010 until 8 December 2010 109
Cardiology Department, Triemlispital, Zurich, Switzerland 30 November 2009 until 28 October 2010 110
Thoraxcentrum Twente, University of Twente, Enschede, The Netherlands 5 January 2010 until 11 December 2010 100
Division of Cardiology, University Hospital, Geneva, Switzerland 17 February 2010 until 16 January 2011 83
Cardiocentro, Lugano, Switzerland 28 January 2010 until 9 November 2010 56
Rabin Medical Centre, Tel Aviv University, Tel Aviv, Israel 2 May 2010 until 16 October 2010 48
Cardiology Department, Zurich University Hospital, Zurich, Switzerland 5 March 2010 until 25 January 2011 44
Herzzentrum Bodensee, Kreuzlingen, Switzerland 5 July 2010 until 22 October 2010 16
Total 17 September 2009 – 25 January 2011 1,161
of 1,161 patients were randomly assigned to treatment with biolimus-
eluting stents with biodegradable polymer or bare metal stents at 11 
sites in Europe and Israel: Switzerland (five), Denmark (one), Israel 
(one), Serbia (one), The Netherlands (one), United Kingdom (one). 
Individual sites and the respective recruitment numbers are shown in 
Table 2. A total of 2,575 patients presented with ST-elevation MI dur-
ing the entire inclusion period at 11 study sites, resulting in inclusion of 
45.1% of patients in the COMFORTABLE AMI trial. The number of 
patients with exclusion criteria (e.g., patients with mechanical ventila-
tion, unable to provide informed consent) as compared to eligible 
patients who did not agree to participate was not assessed. The ran-
domisation procedure was facilitated by an electronic web database 
“Cardiobase” (Copyright by Cardiology Department, CTU Bern, 
Switzerland and 2mT software GmbH, Ulm, Germany). The allocation 
sequence was computer-generated and stratified according to centre.
PROCEDURE
After visualisation of the culprit lesion, thrombus aspiration was rec-
ommended in all patients whenever aspiration was deemed technically 
feasible. Predilatation of the culprit lesion was left to the discretion of 
the operator. The randomly allocated stent had to be implanted in the 
culprit lesion of the target vessel and in all non-culprit lesions of the 
target vessel. As the superiority of DES over BMS has been convinc-
ingly established for the treatment of stable lesions, the use of a bioli-
mus-eluting stent with biodegradable polymer was mandatory among 
all patients with multivessel disease requiring revascularisation of non-
culprit vessels. It was advised to perform staged procedures within the 
first three months. At selected sites (Bern, Copenhagen, Geneva, 
Lugano, Zurich), intravascular ultrasound and optical coherence 
tomography of the culprit lesion after successful stent implantation 
with an angiographically satisfying result was performed as part of an 
imaging substudy (IBIS-4, NCT00962416).
STUDY	DRUGS
The routine use of prasugrel (loading and maintenance) was recom-
mended as a standard P2Y12 inhibitor. If prasugrel was not availa-
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ble, clopidogrel could be used as an alternative antiplatelet drug. 
Prior to the procedure, aspirin at a dose of at least 300 mg and a 
loading dose of 60 mg prasugrel (including patients preloaded with 
clopidogrel) was mandatory. If prasugrel was not available or con-
traindicated, clopidogrel was administered at a loading dose of 
600 mg. During the procedure, unfractionated heparin was given at 
a dose of at least 5000 IE or 70-100 IE/Kg to maintain an activated 
clotting time (ACT) >250 seconds, or alternatively bivalirudin. The 
use of glycoprotein IIb/IIIa inhibitors was left to the discretion of 
the operator. After the procedure, it was recommended to adminis-
ter prasugrel at a dose of 10 mg per day for at least 12 months. If 
prasugrel was not available or contraindicated, clopidogrel was 
given at a dose of 75 mg twice daily for seven days followed by 
a maintenance dose of 75 mg once daily (1-0-0) for at least 
12 months. Following successful primary PCI, it was recommended 
to provide antithrombotic treatment according to local practice.
PRE-SPECIFIED	ANALYSES
Stratified analysis across major clinical subgroups will be per-
formed using multivariate logistic regression or Cox proportional 
hazards models. Subgroup analyses of the primary and major sec-
ondary endpoints will be performed with respect to age, gender, 
diabetes, renal insufficiency, lesion and stent characteristics includ-
ing ostial/bifurcation lesions, differences in antiplatelet treatment 
strategies, SYNTAX score pre- and post-wiring of the target vessel, 
radial versus femoral access, biomarkers, lipid profile, and patients 
with recurrent instable angina without evident disease progression. 
Rates of bleeding and bleeding severity will be analysed according 
to antiplatelet strategy (clopidogrel versus prasugrel).
SUBSTUDIES
A total of 103 patients at five centres (Bern, Copenhagen, Geneva, 
Lugano, Zurich) underwent intracoronary imaging with the use of 
gray-scale intravascular ultrasound, virtual histology IVUS and fre-
quency domain optical coherence tomography (FD-OCT) of the cul-
prit lesion immediately after stent implantation and at 13-month 
follow-up. The aim is to assess the stent vessel wall interactions in 
terms of volumetric measures such as lumen, stent, vessel area, 
neointimal area, apposition, coverage, plaque volume and composi-
tion behind the struts and at the stent edge. All patients undergoing 
intracoronary imaging of the culprit lesion will undergo quantitative 
coronary analysis in order to assess reference and minimal lumen 
diameter, percent diameter stenosis, as well as late lumen loss.
DEFINITIONS
MACE is defined as the composite of cardiac death, MI of the tar-
get vessel, and target lesion revascularisation. Myocardial infarc-
tion was defined according to the extended historical definition29 
and definite, probable and possible stent thrombosis according to 
the Academic Research Consortium30. A more detailed outline of 
the definition applied in the COMFORTABLE AMI trial is pro-
vided in the appendix. All endpoints will be adjudicated by an inde-
pendent event adjudication committee.
DATA	COLLECTION
All patient data are collected and entered into study-specific 
electronic case report forms by the study personnel on site. 
Central and on-site data monitoring is performed by the Clini-
cal Trials Unit Bern, Switzerland. In the participating centres 
in Serbia and Israel, a contract monitoring company performed 
the monitoring according to a pre-specified monitoring plan. 
All electronic case record forms underwent central monitoring. 
Complete case record forms of the first 10 patients followed by 
a random sample of 10% of the remaining patient number at 
each centre underwent on-site monitoring. Preliminary and 
definite written consent were verified in 100% of cases. Patient 
files of 25% of patients were completely monitored with 
respect to event reporting. The database was held and supplied 
by the Clinical Trials Unit Bern, Switzerland.
Conclusion
The COMFORTABLE AMI trial is a large scale, randomised, 
assessor blind, multicentre, international study with a total of 1,161 
enrolled patients, which will determine whether biolimus-eluting 
stents with biodegradable polymer are superior to bare metal stents 
of otherwise identical design. This is the first RCT investigating 
DES with biodegradable polymer surface coating for drug release 
in the treatment of patients with STEMI.
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Appendix
STUDY	ORGANISATION
Sponsor: Clinical Trials Unit Bern, Bern, Switzerland and Cardiol-
ogy Department, Bern University Hospital, Bern, Switzerland
Funding: Unrestricted grant from the Swiss National Science Foun-
dation (Grant 33CM30-124112), Bern, Switzerland; Biosensors 
Europe S.A., Morges, Switzerland
Steering committee: Lorenz Räber, Peter Jüni, Stephan Windecker
Clinical adjudication committee: Pascal Vranckx, Hasselt, Belgium 
(Chair); Gerrit Hellige, Aarau, Switzerland; Igal Moarof, Aarau, 
Switzerland
Data coordination and analysis: Clinical Trials Unit Bern, Bern 
University Hospital, Switzerland (Dik Heg, Sven Trelle, Peter Jüni)
Site management and on-site data monitoring: Clinical Trials Unit 
Bern, Bern, Switzerland (Brigitte Wanner, Anna Plym, Lucia Kac-
ina); Focus, Belgrade, Serbia (Dragana Trifunovic); Ben Gurion 
University, Israel Monitor Tel Aviv (Leonid Kalichman), Tel Aviv, 
Israel
Central monitoring: Clinical Trials Unit Bern, Bern University Hos-
pital, Bern, Switzerland (Sandro Baumgartner, Timon Spörri)
Data safety and monitoring board: Jonathan Sterne, Bristol, United 
Kingdom (chair); Michel E. Bertrand, Lille, France; Phillipe Urban, 
Geneva, Switzerland
Qualitative and quantitative coronary angiographic core labora-
tory: Cardiology Department, Bern University Hospital, Bern, 
Switzerland (Lorenz Räber, Masanori Tanikawi)
Intravascular ultrasound core laboratory analysis: Cardialysis BV, 
Rotterdam, The Netherlands (HM Garcia-Garcia)
Optical coherence tomography analysis: Cardialysis B.V., Rotter-
dam, The Netherlands (HM Garcia-Garcia)
SECONDARY	ENDPOINTS
All cause death; death or MI; cardiac death or MI; any MI (Q-wave 
and non-Q-wave); target vessel failure (composite of cardiac death, 
target vessel MI, target vessel revascularisation); composite of 
death or MI or target vessel revascularisation; target vessel revascu-
larisation; any revascularisation; Academic Research Consortium 
definite, probable and possible stent thrombosis; repeat hospitalisa-
tion due to angina. Additional endpoints that are not directly related 
to the stent comparison include: transient ischaemic attacks; stroke; 
bleeding according to Thrombolysis In Myocardial Infarction 
(TIMI), Global Use of Strategies to Open Occluded Arteries 
(GUSTO) and Bleeding Academic Research Consensus (BARC); 
renal insufficiency according to Risk, Injury, Failure, Loss, and 
End-stage kidney disease (RIFLE); access site complications.
ENDPOINT	DEFINITIONS
1. Death
Cardiac death: All deaths are considered cardiac unless an unequiv-
ocal non-cardiac cause can be established.
Vascular death: Death caused by non-coronary vascular causes, 
such as cerebrovascular disease, pulmonary embolism, ruptured 
aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above 
definitions, including death due to infection, sepsis, pulmonary 
causes, accident, suicide or trauma.
2. Myocardial infarction
Target vessel myocardial infarction is any infarction that is not 
clearly attributable to a non-target vessel.
2.1.1 Spontaneous Q-wave MI (>48 hours after index intervention)
The diagnosis of Q-wave myocardial infarction requires new patho-
logical Q-waves in two or more contiguous ECG leads. Elevated 
cardiac biomarkers or a history of chest pain or other acute symp-
toms consistent with myocardial ischaemia are supportive of the 
diagnosis and should be documented but not needed to make the 
diagnosis (silent myocardial infarction).
2.1.2 Spontaneous non-Q-wave MI (>48 hours after index intervention)
Appropriate cardiac enzyme data (respecting top down hierar-
chy): 1) CKMB >1*URL, or 2) in the absence of CKMB, stand-
ard troponin >1*URL (high sensitivity troponin is considered as 
missing troponin), or 3) in the absence of troponin and CKMB: 
CEC decision upon clinical scenario and with guidance of high 
sensitivity troponin. The appropriate enzyme data should be 
considered in conjunction with at least one of the following 
parameters: 1) evidence of myocardial ischaemia as recognised 
by clinical symptoms, or 2) evidence of myocardial ischaemia as 
recognised by electrocardiographic changes, or 3) evidence of 
myocardial ischaemia as recognised by cardiac imaging of new 
loss of viable myocardium or new regional wall motion 
abnormality.
2.2.1 Baseline biomarkers of myocardial damage: CK and/or 
CK-MB >1xURL or acute MI in progress
Scenario A) CK (or CK-MB) from index MI has not yet reached its 
maximum level: recurrent thoracic chest pain or ischaemia equiva-
lent >20 minutes (or new ECG changes consistent with MI) and 
appropriate cardiac enzyme data: 1) a rise in CK within 24 hours of 
the index event >2*URL (confirmed by either CK-MB or troponin 
>1*URL) and ≥50% above the previous level, or 2) in the absence 
of CK: a (post-PCI) rise in CK-MB within 24 hours of the index 
event >3*URL and ≥50% above the previous level, or 3) in the 
absence of CK and CK-MB: a (post-PCI) rise of troponin within 
24 hours of the index event >3*URL and ≥50% above the previous 
level.
Scenario B) Elevated CK (or CK-MB) following the index MI has 
peaked and CK level has returned <URL then any new rise in: 
1) CK >2*URL (confirmed by either CK-MB >URL or troponin 
>URL), or 2) in the absence of CK: CK-MB >3*URL, or 3) in the 
absence of CK and CK-MB, troponin >3*URL.
Scenario C) CK (or CK-MB) following the index MI has peaked 
and CK level has not returned <URL: 1) a rise in CK ≥50% above 
the previous level and >2 URL confirmed by either CKMB >URL 
or troponin >URL, or 2) in the absence of CK, when CKMB has not 
returned <URL, a rise in CKMB ≥50% above the previous level 
and >3 URL, or 3) in the absence of CK, when CKMB and troponin 
has not returned <URL a rise in troponin ≥50% above the previous 
level and >3*URL.
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2.2.2 Baseline biomarkers of myocardial damage (CK and 
CK-MB and trop< 1*URL) and no acute MI in progress
Scenario A) New pathologic Q-waves in ≥2 contiguous ECG leads 
and: 1) any CK-MB >1*URL, or 2) in the absence of CK-MB: tro-
ponin >1*URL, or 3) in the absence of CK-MB and troponin: CK 
>1*URL, or 3) in the absence of CK-MB and troponin and CK: 
CEC decision upon clinical scenario.
Scenario B) Appropriate cardiac enzyme data: 1) CK ≥2* URL con-
firmed by either CK-MB >1*URL, or 2) in the absence of CK-MB: 
troponin >1*URL, or 3) in the absence of CK-MB and troponin: 
CEC decision upon clinical scenario. In the absence of CK: CK-MB 
>3*URL or in the absence of CK and CK-MB: troponin >3*URL.
Target vessel myocardial infarction
Any myocardial infarction not clearly attributable to a non-target vessel.
Target vessel (TV)
The TV is defined as the index major coronary artery (LAD, LCX 
or RCA and its side branches), which was in physical contact with 
any component (guiding catheter, guidewire, balloon catheter, etc.) 
of the angioplasty hardware during the initial procedure.
Target lesion (TL)
The target lesion is the treated lesion starting 5 mm proximal of the 
stented lesion and ending 5 mm distal of the stented lesion.
Target lesion revascularisation (TLR)
TLR is defined as any repeat percutaneous intervention of the target 
lesion or bypass surgery of the target vessel. All TLR will be recorded 
in the CRF (re-intervention justification form) and be classified pro-
spectively as justified or non-justified by the investigator prior to the 
re-intervention as well as retrospectively by the independent angio-
graphic core laboratory (in the case of percent diameter stenosis).
Clinically indicated revascularisation
Angiography at follow-up shows a percent diameter stenosis ≥50% 
(quantitative coronary angiography [QCA]) and if one of the following 
occurs: a positive history of recurrent angina pectoris presumably 
related to the target vessel; or objective signs of ischaemia at rest or 
during exercise tests presumably related to the target vessel; or abnor-
mal results of any invasive functional diagnostic test. A TLR with a 
diameter stenosis ≥70% (QCA) in the absence of the above-mentioned 
ischaemic signs or symptoms is also considered justified. On the con-
trary, non-clinically indicated TLR are interventions for all stenoses 
<50% in the presence or absence of ischaemic signs or symptoms or all 
stenoses ≥50% but <70% without ischaemic signs or symptoms.
Device success
Achievement of a final diameter stenosis of <50% as measured by 
quantitative coronary angiography (QCA) during the initial proce-
dure with the use of the study stent only.
Lesion success
Achievement of a final diameter stenosis of <50% as measured by 
quantitative coronary angiography (QCA) during the initial proce-
dure with the use of any device.
Procedural success
Clinical devices success (<50% post-procedural stenosis with study 
stent) together with the absence of any in-hospital major adverse 
cardiac events.
Stent thrombosis
Definite, probable and possible stent thrombosis is defined accord-
ing to the Academic Research Consortium.
Transient ischaemic attack
Rapidly developed clinical signs of global disturbance of cerebral 
function lasting <24 hours, regardless of the presence of an acute 
clinically relevant brain lesion in imaging.
Ischaemic stroke
Rapidly developed clinical signs of focal or global disturbance of 
cerebral function lasting >24 hours with imaging of an acute clini-
cally relevant brain lesion. Ischaemic cerebral infarctions with con-
version to haemorrhage are listed here. The diagnosis of a intracerebral 
haemorrhage must be confirmed by cerebral imaging.
Bleeding
Bleeding will be defined according to the TIMI31, GUSTO32, and 
BARC33 criteria as defined elsewhere.
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